CTRI/2010/091/001258已完成4 期
An observational, multinational, multi-center, prospective, open-label study to asses effectiveness, safety and tolerability of treatment with vildagliptin or vildagliptin plus metformin (SPC) in type 2 diabetes mellitus patients in a real-world setting - GUARD
ovartis Healthcare Pvt LtdSandoz house Dr ABRoad WorliMumbai0 个研究点目标入组 20,000 人开始时间: 待定最近更新:
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 发起方
- 入组人数
- 20,000
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Pms
入排标准
入选标准
- •? Male or female outpatients (age ≥ 18 years) with a diagnosis of T2DM who have, within the previous 4 weeks, been prescribed vildagliptin on top of metformin therapy (free dose combination or SPC) or (only if approved in the relevant country) are OAD drug naïve patients who have been prescribed vildagliptin as initial monotherapy.
- •? Patients who consent to have their data collected. Patients will not need to consent to taking the drug, as their treatment is decided before entry into the study and is part of their medical care
排除标准
- •Patients with an HbA1c value greater than 10%Contraindications mentioned in the Summary of Product Characteristics for vildagliptin, metformin and vildagliptin plus metformin SPC
研究者
相似试验
招募中
4 期
Aliskiren in Hypertension: Efficacy and sAfety stuDy (AHEAD)CTRI/2010/091/000645ovartis Healthcare Pvt. Limited, Sandoz House, Shivsagar Estate, Dr. Annie Besant Road, Worli , Mumbai - 400018. Ph: +91 22 2498 8888, Fax: +91 22 2495 41121,500
已完成
3 期
A multi-national clinical trial to evaluate the efficacy and safety of LC15-0444 ;as compared to sitagliptin added to ongoing metformin therapy in patients with Type II diabetes inadequately controlled with metformin alone.CTRI/2010/091/000364G Life Sciences426
进行中（未招募）
1 期
A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) Multiple Sclerosis (MS) Estudio multinacional, multicéntrico, randomizado, doble ciego, en grupos paralelos, para comparar la eficacia, la tolerabilidad y seguridad del Acetato de Glatiramero inyectable 40 mg/ml frente a Acetato de Glatiramero inyectable 20 mg/ml una vez al día en inyección subcutánea en pacientes con Esclerosis Múltiple Remitente Recurrente (EM-RR) - FORTERelapsing-remitting Multiple Sclerosis (RR MS)MedDRA version: 8.1 Level: PT Classification code 10028245EUCTR2006-002037-20-ESTeva Pharmaceutical Industries, Ltd.980
进行中（未招募）
不适用
A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) Multiple Sclerosis (MS) - FORTERelapsing-remitting Multiple Sclerosis (RR MS)MedDRA version: 8.1Level: PTClassification code 10028245EUCTR2006-002037-20-DETeva Pharmaceutical Industries, Ltd.980
进行中（未招募）
不适用
A multi-national, multi-centre, randomized, parallel-group, double-blind study to compare the efficacy, tolerability and safety of Glatiramer Acetate Injection 40 mg/ml to that of Glatiramer Acetate Injection 20 mg/ml administered once daily by subcutaneous injection in subjects with relapsing remitting (RR) Multiple Sclerosis (MS) - FORTEEUCTR2006-002037-20-CZTeva Pharmaceutical Industries, Ltd.980